MBX Smart Money
MBX Biosciences, Inc. Common Stock
1W: -4.2%
1M: -6.2%
3M: -16.3%
YTD: +64.6%
1Y: +211.8%
$52.97
+2.68 (+5.33%)
After Hours: $54.59 (+1.62, +3.05%)
Weekly Expected Move ±8.3%
$40
$44
$48
$53
$57
Credit Risk of going bust: lower than 78% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), MBX Biosciences, Inc. Common Stock would be worth roughly what it owes.
Total debt $3.3M against a stock market value of $2.42B.
Distance to default 9.14 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.7M (short-term plus half of long-term), stock volatility 76.9%; Altman Z'' 18.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), MBX Biosciences, Inc. Common Stock would be worth roughly what it owes.
Total debt $3.3M against a stock market value of $2.42B.
Distance to default 9.14 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.7M (short-term plus half of long-term), stock volatility 76.9%; Altman Z'' 18.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 2026198
Institutions Holding
+21 vs prior
125.1%
Ownership
+61.61%
42
New
63
Increased
70
Reduced
21
Closed
👔 Insider Trades
20 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-04 | Azoulay Salomon | officer: chief medical officer | S-Sale | 370 | $65.77 | $24K | Filing |
| 2026-08-03 | Smither John W | officer: chief financial officer | A-Grant/Award | 28,000 | $— | $0 | Filing |
| 2026-08-03 | Hoerter Steven L. | officer: president and ceo | A-Grant/Award | 71,000 | $— | $0 | Filing |
| 2026-05-08 | Azoulay Salomon | officer: chief medical officer | S-Sale | 55,000 | $38.38 | $2.1M | Filing |
| 2026-05-08 | Azoulay Salomon | officer: chief medical officer | S-Sale | 15,003 | $38.30 | $575K | Filing |
| 2026-05-06 | Hawryluk P. Kent | officer: president & ceo | S-Sale | 607 | $29.54 | $18K | Filing |
| 2026-05-06 | Azoulay Salomon | officer: chief medical officer | S-Sale | 231 | $29.54 | $7K | Filing |
| 2026-05-01 | Hoerter Steven L. | director | A-Grant/Award | 11,938 | $— | $0 | Filing |
| 2026-03-13 | Hawryluk P. Kent | officer: president & ceo | P-Purchase | 18,500 | $28.41 | $526K | Filing |
| 2026-02-02 | Azoulay Salomon | officer: chief medical officer | A-Grant/Award | 15,000 | $— | $0 | Filing |
| 2026-02-02 | Bartram Richard | officer: chief financial officer | A-Grant/Award | 15,000 | $— | $0 | Filing |
| 2026-02-02 | Hawryluk P. Kent | officer: president & ceo | A-Grant/Award | 35,250 | $— | $0 | Filing |
| 2025-10-20 | Hawryluk P. Kent | officer: president & ceo | P-Purchase | 20,000 | $13.64 | $273K | Filing |
| 2025-10-17 | Hoerter Steven L. | director | P-Purchase | 20,000 | $13.25 | $265K | Filing |
| 2025-09-26 | Heron Patrick J | director | P-Purchase | 666,666 | $18.00 | $12.0M | Filing |
| 2025-09-26 | FHMLS X, L.P. | 10% owner | P-Purchase | 666,666 | $18.00 | $12.0M | Filing |
| 2025-09-26 | FHMLS X, L.L.C. | 10% owner | P-Purchase | 666,666 | $18.00 | $12.0M | Filing |
| 2025-09-26 | Topper James N | 10% owner | P-Purchase | 666,666 | $18.00 | $12.0M | Filing |
| 2025-09-26 | Frazier Life Sciences X, L.P. | 10% owner | P-Purchase | 666,666 | $18.00 | $12.0M | Filing |
| 2025-04-08 | Pescovitz Ora H. | director | P-Purchase | 7,693 | $5.89 | $45K | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6,652,013 | $367M | — | 2026-06-30 | Filing |
| FMR LLC | 5,322,885 | $294M | +2,386,201 | 2026-06-30 | Filing |
| WELLINGTON MANAGEMENT GROUP LLP | 4,977,523 | $275M | +1,785,699 | 2026-06-30 | Filing |
| NEA Management Company, LLC | 3,614,486 | $200M | — | 2026-06-30 | Filing |
| ORBIMED ADVISORS LLC | 3,428,736 | $189M | -209,151 | 2026-06-30 | Filing |
| BlackRock, Inc. | 3,323,672 | $183M | +382,266 | 2026-06-30 | Filing |
| Paradigm Biocapital Advisors LP | 2,508,015 | $138M | +2,508,015 | 2026-06-30 | Filing |
| NVP ASSOCIATES, LLC | 2,136,335 | $118M | — | 2026-06-30 | Filing |
| Deep Track Capital, LP | 1,732,569 | $96M | -1,025,000 | 2026-06-30 | Filing |
| Polar Capital Holdings Plc | 1,608,514 | $89M | -13,672 | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,477,388 | $82M | -204 | 2026-06-30 | Filing |
| Aaron Wealth Advisors LLC | 1,167,799 | $64M | -377 | 2026-06-30 | Filing |
| Driehaus Capital Management LLC | 1,056,579 | $58M | +38,367 | 2026-06-30 | Filing |
| Kynam Capital Management, LP | 934,799 | $52M | — | 2026-06-30 | Filing |
| Woodline Partners LP | 900,092 | $50M | +29 | 2026-06-30 | Filing |
| EVENTIDE ASSET MANAGEMENT, LLC | 873,492 | $48M | -16,508 | 2026-06-30 | Filing |
| STATE STREET CORP | 864,466 | $48M | +77,258 | 2026-06-30 | Filing |
| Parkman Healthcare Partners LLC | 800,173 | $44M | +136 | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 773,072 | $43M | +102,687 | 2026-06-30 | Filing |
| BRAIDWELL LP | 710,880 | $39M | -781,587 | 2026-06-30 | Filing |